Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the azure-1 Study of Brelovitug in Chronic Hepatitis Delta Virus Business Wire (Press Release) 1d
Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B Business Wire (Press Release) 10h
Mirum pharmaceuticals announces primary endpoint met in phase 2b portion of the azure-1 study of brelovitug in chronic hepatitis delta virus Business Wire (Press Release) 1d Global Health
Precision receives CTA approval to expand ELIMINATE-B study Hospital Management 09:41 Thu, 16 Apr CRISPR/Gene Editing Science
Africa: Efforts to Eliminate Hepatitis Delivers Gains but More Action Needed to Meet 2030 Targets AllAfrica 9h WHO Hepatitis
Efforts to eliminate hepatitis delivers gains but more action needed to meet 2030 targets World Health Organisation (Press Release) 10h WHO Hepatitis
Mum says boy's condition means family cannot go out BBC 11h Men's Mental Health England Mental Health
BBC star 'hours from fatal heart attack', doctor tells him The Mirror 15h Heart Disease Health & Fitness Article paywall
